Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Fraser

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cancer|April 6, 2023
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myelomaNaresh Bumma, Binod Dhakal, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 DecadesDeepak Kilari, Anita D'Souza, Raphael Fraser, et al.
Bone Marrow Transplantation|October 5, 2021
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysisOren Pasvolsky, Moshe Yeshurun, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2018
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple MyelomaSathish Gopalakrishnan, Anita D'Souza, Emma Scott, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2018
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between GroupsEmma C Scott, Parameswaran Hari, Sathish Kumar, et al.
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Leukemia|April 22, 2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cancer|April 6, 2023
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myelomaNaresh Bumma, Binod Dhakal, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 DecadesDeepak Kilari, Anita D'Souza, Raphael Fraser, et al.
Bone Marrow Transplantation|October 5, 2021
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysisOren Pasvolsky, Moshe Yeshurun, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2018
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple MyelomaSathish Gopalakrishnan, Anita D'Souza, Emma Scott, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2018
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between GroupsEmma C Scott, Parameswaran Hari, Sathish Kumar, et al.
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Leukemia|April 22, 2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Pageof 3